Oorja Bio Launches With $30M Series A for IPF Peptide ORJ-001
Oorja Bio launches with $30M Series A for IPF peptide ORJ-001, targeting β1 integrin to reverse established fibrosis ahead...
Quince Acquires Orphai, Raises $115M for LAM-001 Pulmonary Program
Quince acquires Orphai and raises $115M to advance LAM-001, an inhaled rapamycin formulation, through three rare lung disease trials...
Regeneron Pays $50M for Parabilis Peptide Platform Access
Regeneron pays $50M upfront plus $75M equity for access to Parabilis' peptide platform designed to deliver intracellular payloads.
SERB to acquire European rights to Idefirix from Hansa for €115M
SERB acquires European rights to Idefirix from Hansa for €115M, with €110M upfront and €5M contingent on full EMA...
Telix Partners With EDAP TMS and Profound Medical on PSMA-PET Imaging for Prostate Cancer Ablation
Telix partners with EDAP TMS and Profound Medical to integrate PSMA-PET imaging into image-guided prostate cancer ablation workflows.
ARS Pharmaceuticals Q1 2026: $17.5M Revenue, CVS Caremark Decision Key
ARS Pharmaceuticals reports $17.5M Q1 revenue; CVS Caremark formulary decision expected June will determine company's financial runway.
Accro Bioscience Raises $50M Series C for RIPK2 Inhibitor UC Trial
Accro Bioscience secures $50M Series C to advance AC-101, a RIPK2 inhibitor, into Phase IIb trials for ulcerative colitis...
Quince Acquires Orphai, Raises $187M for LAM-001 Pulmonary Programs
Quince acquires Orphai and raises $187M to advance LAM-001, an inhaled rapamycin program, through Phase 2b trials across three...
Regeneron Partners with Parabilis on Antibody-Helicon Conjugates for $125M
Regeneron partners with Parabilis on antibody-helicon conjugates for $125M to target intracellular proteins resistant to existing drug modalities.
Hansa Biopharma licenses IDEFIRIX to SERB for €115M in Europe deal
Hansa Biopharma licenses IDEFIRIX to SERB for €115M upfront, retaining U.S. rights while funding its FDA launch strategy through...